The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Vol.
31
No.
2
January 14, 2005Jan 14, 2005
Free
DOWNLOAD THE PDF

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.

NCI Names 15 to Director’s Consumer Liaison Group.

SAIC-Frederick Makes Awards To Proteomics Research Teams.

Latest State Cancer Statistics Released.

Smokers May Get Cessation Help From Medicare.

Funding Opportunities Listed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account